Search results
Medications for Pulmonary Arterial Hypertension
Verywell Health via Yahoo News· 6 months agoMedically reviewed by Femi Aremu, PharmD Pulmonary hypertension (PH) can be challenging for healthcare professionals to diagnose because of its vague...
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
Zacks via Yahoo Finance· 4 weeks agoMerck MRK announced that the FDA has granted approval to its novel activin signaling inhibitor,...
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
Zacks via Yahoo Finance· 4 weeks agoWhile AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior...
Is Merck Moving Toward Another Blockbuster Drug Launch?
Motley Fool· 1 year agoEarlier this month, Merck (NYSE: MRK) announced that in a phase 3 clinical trial its drug candidate,...
J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH
Zacks via Yahoo Finance· 11 months agoJ&J (JNJ) submits a new drug application for a single tablet combination therapy of macitentan and...
Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept
Zacks via Yahoo Finance· 1 year agoMerck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the...
FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease
Zacks via Yahoo Finance· 7 months agoThe FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with...
Merck Stock Pops After Snagging Its Latest Approval; The First In A Possible $10 Billion...
Investor's Business Daily· 4 weeks agoMerck stock popped Wednesday, pacing the Dow Jones industrials, after winning Food and Drug...
Merck (MRK) Posts Positive Results From PAH Drug Study
Zacks via Yahoo Finance· 2 years agoMerck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary...
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
Investor's Business Daily· 2 years agoThe name Merck is synonymous with Keytruda, a blockbuster cancer treatment. But that isn't what has...